News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Arovella Therapeutics.
RELATED STOCKHEAD STORIES
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
Weed Week: Cannabis can ‘kill melanoma’; and Germany legalises weed possession
Health & Biotech
Weed Week: Iron Mike throws down challenge to Biden, and recent ASX pot winners
Health & Biotech
Fundie Merchant Group picks four biotech stocks that could rip as sector hits rude health again
Health & Biotech
Weed Week: Hey stoners, exercise is even better on weed; and recent ASX pot winners
Health & Biotech
ASX Health Winners January: ‘Invest in business not science’, as SHG and PAA top winners list
Health & Biotech
ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform
News
Rise and Shine: Everything you need to know before the ASX opens
News
CLOSING BELL: ASX 200 banks sixth straight win after Energy stocks drive investors mildly bananas
Health & Biotech
Weed Week: Blow to cannabis as Thailand backpedals on weed law; and recent ASX pot stock winners
Health & Biotech
Weed Week: Cannabis stocks down almost 20pc in 2023, but here’s why they could rebound by Q2 2024
Health & Biotech
Weed Week: Massive study links cannabis to genetics and schizophrenia, and the best ASX weed stocks right now
Health & Biotech
ASX Biotech October Winners: Dimerix, Noxopharm and Chimeric dominate as investors hunt next big thing in pharma
Health & Biotech
Weed Week: US House Speaker ousting could boost weed stocks; TGA urged to allow the term ‘medicinal cannabis’
Health & Biotech
ASX Health Stocks: Arovella to develop a world-first iNKT cell therapy targeting cancers
News
Top 10 at 11: Lithium, gold and old news are propelling the market this morning
News